Aptose Biosciences (APTO) Stock Price, News & Analysis

Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.71 to $6.86
• 52-Week Range: N/A
• Volume: 650,294 shs
• Average Volume: 227,964 shs
• Market Capitalization: $3.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Strong Buy

Aptose Biosciences Stock Analysis - MarketRank™

Aptose Biosciences scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Aptose Biosciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aptose Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aptose Biosciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aptose Biosciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for APTO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aptose Biosciences does not currently pay a dividend.

Dividend Growth

Aptose Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for APTO.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Aptose Biosciences this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aptose Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.33% of the stock of Aptose Biosciences is held by insiders.

Percentage Held by Institutions

Only 26.62% of the stock of Aptose Biosciences is held by institutions.

APTO Stock Analysis - Frequently Asked Questions

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) released its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($12.90) earnings per share for the quarter, beating the consensus estimate of ($17.40) by $4.50.

When did Aptose Biosciences' stock split?

Shares of Aptose Biosciences reverse split on the morning of Wednesday, February 26th 2025.The 1-30 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Digital Turbine (APPS), Okta (OKTA), Canoo (GOEV), CrowdStrike (CRWD) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 8/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APTO
• CIK: 882361
• Web: www.aptose.com
• Phone: 858-926-2730
• Fax: 905-234-2120
• Employees: 31
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aptose Biosciences: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($89.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -5,683.22%
• Return on Assets: -300.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.19) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,141,000
• Free Float: 63,446,000
• Market Cap: $3.66 million
• Optionable: No Data
• Beta: 1.04